Work

Optimizing treatment for platinum‐resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab

Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Platinum-resistant (PR) ovarian clear cell carcinoma (OCCC) is highly resistant to chemotherapy and has a poor prognosis. Both in-vitro and clinical studies have suggested that gemcitabine (GEM) is particularly effective against OCCC. Moreover, a combination with bevacizumab (Bev) is expected to enhance the efficacy of chemotherapy. METHODS: To clarify these effects, the authors conducted a multicenter, retrospective cohort study of 130 patients who received treatment single-agent chemotherapy, with or without Bev, for PR-OCCC. The effects of loss of AT-rich interaction domain 1A (ARID1A) protein expression also were assessed. RESULTS: Patients who received GEM as their first regimen achieved better overall survival (OS) than those who received other agents (median OS, 15.2 vs. 11.0 months; hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.41-0.96; p = .032). Bev combination therapies demonstrated a significantly improved time to treatment failure compared with chemotherapy alone (6.6 vs. 2.7 months; HR, 0.61; 95% CI, 0.41-0.87; p = .009) and showed a trend toward longer OS (23.3 vs. 9.8 months; HR, 0.62; 95% CI, 0.34-1.05; p = .085). ARID1A status did not affect OS in the overall group or in the group that received GEM as the first-line regimen (p = .41 and p = .31, respectively). CONCLUSIONS: Collectively, the current findings suggest that GEM, particularly as a first-line treatment, may improve the prognosis of patients with PR-OCCC. Moreover, Bev combination therapy is a promising option for treating PR-OCCC.
Source: Cancer
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,790
OpenAlex ID: W4413856434
FWCI: 0.737
Cites: 31
Cited by: 3
Related to: 10